Company
Zealand Pharma
Zealand Pharma A/S
Public (NASDAQ Copenhagen:ZEAL) · Søborg, Denmark · Last verified Aug 15, 2024
Peptide-focused biotech; discovered and partnered GLP-1/glucagon dual agonist survodutide.
Company profile
- Legal name
- Zealand Pharma A/S
- Status
- public
- Ticker
- NASDAQ Copenhagen:ZEAL
- Headquarters
- Søborg, Denmark
- Website
- www.zealandpharma.com
Active assets
| Asset | Stage | Indications |
|---|---|---|
| Survodutide | Phase 2 | — |
Trial roll-up
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT05649174 | Phase 2 | A Study to Evaluate Survodutide in Participants With Non-alcoholic Steatohepatitis (NASH) | Active, not recruiting |
Deals
View all →| Parties | Type | Headline value | Announced |
|---|---|---|---|
| Boehringer Ingelheim International GmbH / Zealand Pharma A/S | partnership | Up to $500 million (contingent) | Jun 15, 2011 |